SOURCE: Heat Biologics

Heat Biologics

January 07, 2014 08:05 ET

Heat Biologics, Inc. to Present at Biotech Showcase 2014

Live Webcast of Heat's Presentation on January 14, 2014 at 10:30 a.m. PT

CHAPEL HILL, NC--(Marketwired - Jan 7, 2014) - Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today that Jeff Wolf, Chief Executive Officer, will be presenting a company overview at the 6th Annual Biotech Showcase investor and partnering conference on Tuesday, January 14, 2014 at 10:30 a.m. Pacific (1:30 p.m. Eastern) at the Parc 55 Wyndham - Union Square, San Francisco, CA.

A live audio webcast of the presentation will be available in the Investor Relations section of the Company's website at www.heatbio.com. A webcast replay will be available approximately two hours after the presentation ends and will be accessible for one month.

About Heat Biologics, Inc.
Heat Biologics, Inc. (www.heatbio.com) is a clinical-stage biopharmaceutical company focused on developing its novel, "off-the-shelf" ImPACT therapeutic vaccines to combat a wide range of cancers. Our ImPACT Therapy is designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to "pump out" a broad spectrum of cancer-associated antigens together with a potent immune adjuvant called "gp96" to educate and activate a cancer patient's immune system to recognize and kill cancerous cells. Heat's HS-110 will be entering Phase 2 trials against non-small cell lung cancer and its HS-410 will be entering Phase 1/2 clinical trials against bladder cancer.

Forward Looking Statements
This press release includes forward-looking statements on our current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and include statements regarding the potential for Heat's ImPACT Therapy. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability for Heat's ImPACT Therapy to perform as designed. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

Contact Information

  • Heat Biologics, Inc. Contact Information:
    Matthew Czajkowski
    Chief Financial Officer
    (919) 240 7133
    Email Contact

    Jenene Thomas
    Investor Relations and Corporate Communications Advisor
    Jenene Thomas Communications, LLC
    (908) 938-1475
    Email Contact